華潤三九(000999.SZ):已陸續上市999布洛芬混懸液等產品 流感產品磷酸奧司他韋膠囊已獲批、即將上市
格隆匯5月15日丨華潤三九(000999.SZ)披露投資者關係活動記錄表顯示,公司CHC業務商業模式清晰,未來業務具備一定增長潛力在於:1.品牌是CHC業務的核心競爭力,公司將持續強化品牌力和消費者溝通能力;2.持續豐富品類並陸續補充細分領域產品,培育大品種。如感冒品類中999抗病毒口服液近兩年增長態勢迅猛。同時,公司已陸續上市999布洛芬混懸液等產品,流感產品磷酸奧司他韋膠囊已獲批、即將上市,未來對品類有一定的補充。此外,公司從感冒止咳領域進一步升級到呼吸領域,後續也希望陸續補充哮喘、COPD等領域產品。3.終端和渠道方面具備一定的提升機會。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.